Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Clinical-stage Biopharmaceutical Company Announces $3.2M Registered Direct Offering

GT Biopharma Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules.
GT Biopharma, Inc. (NASDAQ: GTBP) recently announced a major development with the entry into definitive securities purchase agreements for a registered direct offering priced at-the-market under Nasdaq rules. The company disclosed that it has secured the purchase and sale of 740,000 shares of its common stock at a purchase price of $4.35 per share, totaling approximately $3.2 million in gross proceeds before deducting placement agent’s fees and other offering expenses. $GT Biopharma(GTBP.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
4159 Views
Comment
Sign in to post a comment
    150Followers
    0Following
    340Visitors
    Follow